<DOC>
	<DOCNO>NCT02228798</DOCNO>
	<brief_summary>The aim Perioperative Anticoagulant Use Surgery Evaluation ( PAUSE ) Study , establish safe , standardized protocol perioperative management patient atrial fibrillation ( AF ) receive novel oral anticoagulant ( DOAC ) drug , either dabigatran , rivaroxaban apixaban , require elective surgery/procedure .</brief_summary>
	<brief_title>Perioperative Anticoagulant Use Surgery Evaluation Study</brief_title>
	<detailed_description>The primary aim demonstrate standardize patient-focused protocol perioperative management DOAC safe , acceptably low rate perioperative major bleeding ( MB ) arterial thromboembolism ( ATE ) . The perioperative protocol adjust base patient renal function surgery/procedure-related bleed risk , optimize patient safety , involve heparin bridging anticoagulation . The secondary aim PAUSE Study determine effect pre-operative DOAC interruption protocol level residual anticoagulation , measure 'everyday ' coagulation test DOAC-specific ( e.g. , activate partial thromboplastin time [ aPTT ] ) 'specialized ' coagulation test DOAC-specific ( dilute thrombin time [ TT ] - HemoclotTM , anti-factor Xa assay ) . Approximately 3,300 patient 15 25 centre 3.5 year period recruit across Canada PAUSE Study . Patients Atrial Fibrillation currently take dabigatran , rivaroxaban apixaban ( DOACs ) require elective surgery/procedure follow standardized management perioperative protocol discontinuation DOAC prior surgery . Patients discontinue DOAC currently receive 1 4 day prior surgery procedure , depend bleed risk , type DOAC , creatinine clearance rate . A blood sample take day surgery procedure measurement laboratory outcome ( residual level anticoagulant day surgery ) . Patients follow weekly month primary outcome assessment .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>1 . Age 18 year old 2 . Receiving DOAC ( dabigatran rivaroxaban apixaban ) Atrial Fibrillation 3 . Ability assess patient lease one day prior DOAC discontinuation 1 . CrCl le 30 mL per min dabigatran rivaroxabantreated patient ( less 25 mL per min apixabantreated patient ) estimate CockroftGault formula 2 . Cognitive impairment psychiatric illness precludes collection followup data 3 . Inability unwillingness provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>anticoagulant</keyword>
	<keyword>atrial fibrillation</keyword>
	<keyword>surgery</keyword>
	<keyword>oral anticoagulant</keyword>
	<keyword>discontinue</keyword>
	<keyword>DOAC</keyword>
	<keyword>NOAC</keyword>
	<keyword>blood thinner</keyword>
	<keyword>interruption</keyword>
</DOC>